Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Rituximab Gains Two New Indications In The EU

This article was originally published in The Pink Sheet Daily

Executive Summary

MabThera, marketed by Genentech/Biogen Idec in the U.S. as Rituxan, is now approved in Europe for maintenance NHL and RA.

You may also be interested in...



NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway

Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.

NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway

Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.

Rituxan Comes In Like A Lion With Two New Indications

FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.

Topics

UsernamePublicRestriction

Register

PS064486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel